AlphaLISA™ Acceptor beads conjugated to anti-His antibody. The mouse monoclonal antibody detects proteins containing accessible consecutive histidine regions at the amino- or carboxy- terminus. These beads can be used to capture His-tagged proteins and peptides for AlphaLISA no-wash assays.
This is a replacement for AL128.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Protein-Protein Interaction |
AlphaLISA™ Acceptor beads conjugated to anti-His antibody. The mouse monoclonal antibody detects proteins containing accessible consecutive histidine regions at the amino- or carboxy- terminus. These beads can be used to capture His-tagged proteins and peptides for AlphaLISA no-wash assays.
This is a replacement for AL128.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
These beads can be used to capture His-tagged proteins and peptides, and can be used in conjunction with Alpha Donor beads to create AlphaLISA™ no-wash assays for:
In a typical AlphaLISA assay, 1 mg of Acceptor beads is sufficient to run 1,000-2,000 wells using a 50 μL reaction volume.
Features:
AlphaScreen® and AlphaLISA™ are bead-based assay technologies used to study biomolecular interactions in a microplate format. The acronym "Alpha&quit; stands for amplified luminescent proximity homogeneous assay. As the name implies, some of the key features of these technologies are that they are non-radioactive, homogeneous proximity assays. Binding of molecules captured on the beads leads to an energy transfer from one bead to the other, ultimately producing a luminescent/fluorescent signal. To understand how a signal is produced, one must begin with an understanding of the beads. AlphaScreen and AlphaLISA assays require two bead types: Donor beads and Acceptor beads. Each bead type contains a different proprietary mixture of chemicals, which are key elements of the AlphaScreen technology. Donor beads contain a photosensitizer, phthalocyanine, which converts ambient oxygen to an excited and reactive form of O2, singlet oxygen, upon illumination at 680 nm. Please note that singlet oxygen is not a radical; it is molecular oxygen with a single excited electron. Like other excited molecules, singlet oxygen has a limited lifetime prior to falling back to ground state. Within its 4 μsec half-life, singlet oxygen can diffuse approximately 200 nm in solution. If an Acceptor bead is within that proximity, energy is transferred from the singlet oxygen to thioxene derivatives within the Acceptor bead, subsequently culminating in light production at 520-620 nm (AlphaScreen) or at 615 nm (AlphaLISA). In the absence of an Acceptor bead, singlet oxygen falls to ground state and no signal is produced. This proximity-dependent chemical energy transfer is the basis for AlphaScreen's homogeneous nature.
Application |
Protein-Protein Interaction
|
---|---|
Automation Compatible |
Yes
|
Bead Type or Material |
AlphaLISA Acceptor
|
Brand |
AlphaLISA
|
Conjugates |
Anti-6X His
|
Detection Modality |
Alpha
|
Product Group |
Beads
|
Shipping Conditions |
Shipped in Blue Ice
|
Target Class |
Binding Assay
|
Technology |
Alpha
|
Unit Size |
250 µg
|
Are you looking for resources, click on the resource type to explore further.
Electrophoretic Mobility Shift Assay (EMSA) is a standard technique used to study protein-DNA interactions. It is a radioactive...
Alpha has been used to study a wide variety of interactions, including protein:protein, protein:peptide, protein:DNA, protein:RNA...
Fc Gamma Receptors (FcγRs) are critical for the function of therapeutic antibodies and mediate many effector functions.
Therapeutic...
Due to limitations driven by circulatory half-life and drug target bioavailability, injected biologics often require the injection...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating...
We are here to answer your questions.